The trial evaluated the effectiveness of AstraZeneca’s camizestrant, an investigational next-generation oral selective ...

“The clinical data we recently presented supports rapid advancement of azenosertib as a monotherapy therapy for patients with Cyclin E1+ PROC, and the continued development of azenosertib in ...

Positive azenosertib clinical data demonstrated clinically meaningful results in patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC) Topline data from registration-intent DENALI Part ...

Cancer drugs that inhibit CDK7 rapidly shut down pathways responsible for cell proliferation within minutes. For organs to ...

Drs Ursula A. Matulonis and Gini F. Fleming discuss the state of endometrial cancer, the role of immunotherapy, and ...

Events across the Metroplex have been canceled or delayed as hail and strong winds are expected Saturday morning.

Cyclacel Pharmaceuticals, Inc.’s CYCC share price has dipped by 15.89%, which has investors questioning if this is right time ...

Zentalis Pharmaceuticals, Inc.’s ZNTL share price has dipped by 8.97%, which has investors questioning if this is right time to buy.

For decades, cancer researchers and pharmaceutical companies have eyed cyclin-dependent kinase (CDK7) with interest due to its role as a "master regulator" of cell proliferation. CDK7 does this in ...

StockNews.com started coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS – Free Report) in a research note released on Sunday morning. The brokerage issued a sell rating on the stock. Syros ...

Aprea is advancing APR-1051 as monotherapy in cancers with Cyclin E over-expression, as well as other biomarkers that may predict sensitivity to WEE1 inhibition. Cancers over-expressing Cyclin E ...